Business Context and Reporting Period
Company: Healthcare Acquisition Corp. (Note: Input metadata referenced "Altimmune, Inc.", but the filing text identifies the registrant as Healthcare Acquisition Corp., a Delaware corporation).
Reporting Period: Quarterly period ended June 30, 2006.
Business Model: The Company is a "blank check" company (Special Purpose Acquisition Company) formed on April 25, 2005, to acquire an operating business in the healthcare industry. As of the reporting date, the Company is in the development stage with no substantive commercial operations other than searching for a target business.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2006 | Six Months Ended June 30, 2006 |
|---|---|---|
| Total Revenues | $466,048 | $871,071 |
| Net Income | $283,894 | $488,344 |
| Earnings Per Share (Basic) | $0.02 | $0.04 |
| Cash and Cash Equivalents | $1,002,937 | $1,002,937 |
| Cash Held in Trust | $69,691,507 | $69,691,507 |
| Total Current Liabilities | $575,938 | $575,938 |
| Stockholders' Equity | $56,585,752 | $56,585,752 |
Liquidity: The Company holds approximately $69.7 million in a Trust Fund invested in U.S. Treasury Bills or money market funds. Approximately $1.0 million is held outside the trust for working capital. Management believes funds outside the trust are sufficient to operate through August 2007.
Material Changes vs. Prior Period
- Trust Fund Growth: Cash held in the Trust Fund increased from $68,636,069 at December 31, 2005, to $69,691,507 at June 30, 2006, primarily due to interest and dividend income earned on trust investments ($844,456 for the six-month period).
- Liabilities: Total current liabilities increased from $410,535 to $575,938. This increase was driven by a rise in deferred revenue (related to interest income on shares subject to redemption) from $141,543 to $352,525 and an increase in state income tax payable.
- Operating Expenses: Total expenses for the six months ended June 30, 2006, were $295,727. Major expense categories included capital-based taxes ($66,545), legal fees ($60,204), and general and administrative costs ($37,016).
Outlook, Risks, and Contingencies
- Business Combination Deadline: The Company must consummate a business combination by January 28, 2007 (18 months from the IPO), or July 28, 2007, if extension criteria are met. Failure to do so will result in mandatory liquidation.
- Liquidation Risk: If the Company liquidates, public stockholders will receive the amount in the Trust Fund (net of taxes). Warrants will expire worthless. Initial stockholders have waived their rights to liquidation distributions.
- Third-Party Claims: There is a risk that third parties (vendors, target businesses) may assert claims against the Company. While the Company seeks waivers, there is no guarantee these will be obtained. If claims exceed assets outside the trust, stockholders could potentially be liable for distributions received.
- Redemption Rights: Public stockholders may redeem their shares for a pro-rata share of the Trust Fund if they vote against a proposed business combination. Approximately 19.99% of the Trust Fund is classified as "common stock subject to possible redemption."
- Market Risk: The Company is not currently exposed to foreign exchange or commodity price risks. Interest rate risk is considered minimal due to the short-term nature of Trust Fund investments.
Investor Verification Checklist
- Verify the exact deadline for the mandatory liquidation (January 28, 2007, or July 28, 2007 with extension).
- Confirm the current balance of the Trust Fund and the per-share redemption value available to public stockholders.
- Review the status of any potential target business negotiations, as none are disclosed in this filing.
- Assess the sufficiency of the $1.0 million in working capital outside the trust to cover operating expenses until the liquidation deadline.
- Understand the terms of the Warrants (exercise price of $6.00) and the Purchase Option granted to underwriters.